ECE2017 Eposter Presentations: Reproductive Endocrinology Female Reproduction (62 abstracts)
1Department of Metabolic Diseases, Jagiellonian University, Medical College, Krakow, Poland; 2Department of Gynecological Endocrinology, Jagiellonian University, Medical College, Krakow, Poland; 3University Hospital, Krakow, Poland.
: Hyperinsulinemia is one of biochemical features of polycystic ovary syndrome (PCOS). Metformin is a common drug used in PCOS. Recent studies have shown that metformin has impact on clinical and biochemical parameters in PCOS patients. The aim of our study was to assess retrospectively the influence of metformin on total testosterone, sex hormone binding globulin (SHBG) and free androgen index (FAI) in women with PCOS in polish cohort. A total of 54 patients with PCOS and irregular menses were examined. The duration of metformin treatment between the baseline and final blood results was about six months. There were statistically significant differences in the total testosterone (1.9 (1.42.6) vs 1.2 (0.62) ng/ml), SHBG (34.8 (27.253.1) vs 49.4 (35.981.7) nmol/l) levels and FAI (5.3 (3.29.8) vs 2.3 (1.34.3) before and after the metformin administration (all P<0.0001). In addition the patients were divided into two groups according to FAI. There was no difference in age (29 (2632) vs 28 (2531) years, P=0.7) and BMI (22.5 (1924.1) vs (22 (20.728.1) kg/m2, P=0.35) between group with FAI<5 and group with FAI>5, respectively. Our study showed that metformin therapy ameliorates the total testosterone and FAI both in women with FAI greater and lower 5 but improves SHBG levels only among patients with FAI>5. The groups did not differ in difference between baseline and final testosterone and SHBG levels but differed in FAI change. Our study suggest that metformin effectiveness could differ between PCOS patients according to the phenotype.